Silver Book Fact

One study found that dopaminergenic therapies for Parkinson’s disease patients resulted in lower dyskinesias as well as lower incidences of freezing, drowsiness, and edema–resulting in better quality-of-life through symptom control.

Holloway, Robert G. et al. Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial. Arch Neurol. 2004; 61(7): 1044-53. http://archneur.ama-assn.org/cgi/content/full/61/7/1044

Reference

Title
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-year randomized controlled trial
Publication
Arch Neurol
Publication Date
2004
Authors
Holloway, Robert G. et al.
Volume & Issue
Volume 61, Issue 7
Pages
1044-53
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • A clinical trial in Europe found that treating Alzheimer’s patients with an Alzheimer’s drug reduced annual treatment costs by $1,000 per patient.  
  • An Alzheimer’s disease research study showed that billions of dollars could be saved if physicians could intervene before someone becomes symptomatic. This positive net savings occurred with both drug treatment…  
  • Donepezil, a cholinesterase inhibitor, has been found to slow progression of Alzheimer’s disease in its early stages, delaying the need for nursing home care by an average of 30 months.  
  • If an Alzheimer’s disease treatment breakthrough that delayed the age of onset by 5 years was introduced in 2015, by 2050 out-of-pocket costs for individuals and families dealing with the…  
  • Early Gene Therapy Studies Show Promise for Parkinson’s Disease